AU2015348942B2 - Substituted bridged urea analogs as sirtuin modulators - Google Patents

Substituted bridged urea analogs as sirtuin modulators Download PDF

Info

Publication number
AU2015348942B2
AU2015348942B2 AU2015348942A AU2015348942A AU2015348942B2 AU 2015348942 B2 AU2015348942 B2 AU 2015348942B2 AU 2015348942 A AU2015348942 A AU 2015348942A AU 2015348942 A AU2015348942 A AU 2015348942A AU 2015348942 B2 AU2015348942 B2 AU 2015348942B2
Authority
AU
Australia
Prior art keywords
dodeca
triene
triazatricyclo
dicarboxamide
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015348942A
Other languages
English (en)
Other versions
AU2015348942A1 (en
Inventor
James Lamond ELLIS
Karen Anderson Evans
Ryan Michael Fox
William Henry Miller
Mark Andrew Seefeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of AU2015348942A1 publication Critical patent/AU2015348942A1/en
Application granted granted Critical
Publication of AU2015348942B2 publication Critical patent/AU2015348942B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015348942A 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators Ceased AU2015348942B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
US62/081,916 2014-11-19
PCT/IB2015/058978 WO2016079710A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (2)

Publication Number Publication Date
AU2015348942A1 AU2015348942A1 (en) 2017-06-01
AU2015348942B2 true AU2015348942B2 (en) 2018-07-05

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015348942A Ceased AU2015348942B2 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348941A Abandoned AU2015348941A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as Sirtuin Modulators
AU2015348943A Abandoned AU2015348943A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348944A Abandoned AU2015348944A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2015348941A Abandoned AU2015348941A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as Sirtuin Modulators
AU2015348943A Abandoned AU2015348943A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators
AU2015348944A Abandoned AU2015348944A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Country Status (21)

Country Link
US (4) US20170355705A1 (OSRAM)
EP (4) EP3221322A1 (OSRAM)
JP (4) JP2017534665A (OSRAM)
KR (4) KR20170083134A (OSRAM)
CN (4) CN107108627A (OSRAM)
AU (4) AU2015348942B2 (OSRAM)
BR (4) BR112017010595A2 (OSRAM)
CA (4) CA2968027A1 (OSRAM)
CL (1) CL2017001275A1 (OSRAM)
CO (1) CO2017004994A2 (OSRAM)
CR (1) CR20170209A (OSRAM)
DO (1) DOP2017000123A (OSRAM)
EA (1) EA201791074A1 (OSRAM)
ES (1) ES2823748T3 (OSRAM)
IL (1) IL252252A0 (OSRAM)
MX (1) MX2017006658A (OSRAM)
PE (1) PE20171257A1 (OSRAM)
PH (1) PH12017500913A1 (OSRAM)
RU (3) RU2017120857A (OSRAM)
SG (1) SG11201703824QA (OSRAM)
WO (4) WO2016079710A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653782B2 (en) * 2014-11-25 2020-05-19 Nortwestern University Retroviral particles expressing Sirt1 embedded within PPCN
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
WO2021043703A1 (de) * 2019-09-02 2021-03-11 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
CN114929680B (zh) * 2019-11-19 2024-06-14 印度鲁宾有限公司 制备苯并二氢吡喃化合物的方法
BR112022013865A2 (pt) * 2020-01-17 2022-09-13 Lupin Ltd Métodos e composto
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺
WO2025194094A1 (en) * 2024-03-15 2025-09-18 The Regents Of The University Of Michigan Small molecule modulators of sirt5 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
US9556201B2 (en) * 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
EP2790701A1 (en) * 2011-12-12 2014-10-22 SMB Innovation Novel heterocyclic compounds useful in sirtuin binding and modulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
KR20170087907A (ko) 2017-07-31
BR112017010602A2 (pt) 2017-12-26
RU2017120858A (ru) 2018-12-19
EP3220918A1 (en) 2017-09-27
EP3221317A1 (en) 2017-09-27
CA2968032A1 (en) 2016-05-26
CA2968030A1 (en) 2016-05-26
AU2015348944A1 (en) 2017-06-01
BR112017010601A2 (pt) 2017-12-26
US20170355705A1 (en) 2017-12-14
RU2017120857A (ru) 2018-12-19
EP3221322A1 (en) 2017-09-27
KR20170083134A (ko) 2017-07-17
ES2823748T3 (es) 2021-05-10
CN107207520A (zh) 2017-09-26
JP2017534663A (ja) 2017-11-24
AU2015348941A1 (en) 2017-06-01
US20170362234A1 (en) 2017-12-21
AU2015348942A1 (en) 2017-06-01
RU2017120855A (ru) 2018-12-19
JP2017534662A (ja) 2017-11-24
WO2016079711A1 (en) 2016-05-26
WO2016079709A1 (en) 2016-05-26
KR20170083133A (ko) 2017-07-17
KR20170083135A (ko) 2017-07-17
CA2968027A1 (en) 2016-05-26
EA201791074A1 (ru) 2017-10-31
CN107207521A (zh) 2017-09-26
CN107207509B (zh) 2020-04-21
CN107108627A (zh) 2017-08-29
CR20170209A (es) 2017-07-17
CA2968029A1 (en) 2016-05-26
CN107207509A (zh) 2017-09-26
US20180319810A1 (en) 2018-11-08
JP2017534664A (ja) 2017-11-24
AU2015348943A1 (en) 2017-06-01
MX2017006658A (es) 2018-01-15
IL252252A0 (en) 2017-07-31
WO2016079712A1 (en) 2016-05-26
EP3221317B1 (en) 2020-07-22
CL2017001275A1 (es) 2017-12-15
JP6806679B2 (ja) 2021-01-06
WO2016079710A1 (en) 2016-05-26
PH12017500913A1 (en) 2017-12-04
DOP2017000123A (es) 2017-08-15
EP3221316A1 (en) 2017-09-27
US10072011B2 (en) 2018-09-11
BR112017010595A2 (pt) 2018-01-02
CO2017004994A2 (es) 2017-09-20
PE20171257A1 (es) 2017-08-28
SG11201703824QA (en) 2017-06-29
US20190048016A1 (en) 2019-02-14
JP2017534665A (ja) 2017-11-24
BR112017010599A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
US10072011B2 (en) Substituted bridged urea analogs as sirtuin modulators
EP2768509B1 (en) Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9834558B2 (en) Substituted bridged urea analogs as sirtuin modulators
WO2016081692A2 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired